Meta's neural band in Garmin's Unified Cabin at CES 2026. (Karissa Bell for Engadget) Meta has been experimenting with EMG technology for years. In 2025, the company commercialized it for the first ...
The headline feature is undoubtedly the inclusion of an EMG (Electromyography) sensor. While we’ve seen ECG (Electrocardiogram) sensors become standard for heart health, an EMG sensor is a rarity. It ...
Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people. While it is well known for causing muscle weakness and stiffness, DM1 also ...
A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study also hitting an enrollment target, triggering a $200 milestone payment due ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose ...
What if your muscles could do more than just move your body? Imagine flexing your arm to scroll through a webpage or clenching your fist to control a robotic arm. It sounds like something out of a sci ...
The RNA Institute is located at the University at Albany's uptown campus in Albany, where the Wellstone Center will also have a presence. ALBANY— The University at Albany and Virginia Commonwealth ...
The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker". With ...
WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...
SAR446268 is a one-time adeno-associated viral gene therapy that delivers a vectorized RNA interference to silence DMPK expression. The Food and Drug Administration (FDA) has granted Fast Track ...
Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expression Myotonic dystrophy type 1 (DM1) is a rare, genetic disorder that causes progressive muscle weakness and ...
(RTTNews) - Dyne Therapeutics Inc. (DYN), a clinical-stage company developing treatments for genetically driven neuromuscular diseases, is advancing its programs in Myotonic Dystrophy and Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results